ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
16 Aug 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March

13/03/2008 12:00pm

PR Newswire (US)


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Sunesis Pharmaceuticals Charts.
SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Daniel Swisher, Sunesis' Chief Executive Officer and President, will provide a corporate overview at two upcoming investor conferences in March. -- Mr. Swisher will speak at the Cowen and Company 28th Annual Health Care Conference at 8:45 a.m. Eastern Time on Tuesday, March 18, 2008 at the Boston Marriott Copley Place in Boston, Mass. -- On Thursday, March 20, 2008, Mr. Swisher will present at the Lehman Brothers Eleventh Annual Global Healthcare Conference at 12:45 p.m. Eastern Time in Miami, Fla. Interested parties may access a webcast of each the presentations by visiting the Sunesis website at http://ir.sunesis.com/. A replay of the webcasts will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks. About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com/. DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: Investors, Eric Bjerkholt, SVP, Corp. Development & Finance of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or Media, Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners for Sunesis Pharmaceuticals, Inc. Web site: http://www.sunesis.com/

Copyright

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock